Voriconazole-associated cutaneous malignancy: A literature review on photocarcinogenesis in organ transplant recipients

Clinical Infectious Diseases

Volumn 58, Issue 7, 2014, Pages 997-1002

  Williams, Kiyanna ^a   Mansh, Matthew ^b   Chin Hong, Peter ^a   Singer, Jonathan ^a   Arron, Sarah Tuttleton ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Organ transplant; Photocarcinogenesis; Skin cancer; Squamous cell carcinoma; Voriconazole

Indexed keywords

VORICONAZOLE; ANTIFUNGAL AGENT;

ARTICLE; DISEASE ASSOCIATION; GRAFT RECIPIENT; HUMAN; MELANOMA; MULTICENTER STUDY (TOPIC); ORGAN TRANSPLANTATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; SKIN CARCINOMA; AGE; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; FEMALE; MALE; PHOTOSENSITIVITY DISORDERS; RISK FACTOR; SEX DIFFERENCE; SKIN NEOPLASMS; UNITED STATES;

AGE FACTORS; ANTIFUNGAL AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; MELANOMA; PHOTOSENSITIVITY DISORDERS; RISK FACTORS; SEX FACTORS; SKIN NEOPLASMS; TRANSPLANT RECIPIENTS; UNITED STATES; VORICONAZOLE;

EID: 84908671512     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit940     Document Type: Article

References (37)

1. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1-17; quiz 18-20.
2. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part 1. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65:253-61; quiz 62.
3. Lindelof B, Jarnvik J, Ternesten-Bratel A, Granath F, Hedblad MA. Mortality and clinicopathological features of cutaneous squamous cell carcinoma in organ transplant recipients: a study of the Swedish cohort. Acta Derm Venereol 2006; 86:219-22.
4. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36:167-74.
5. Roeger LS, Sheil AGR, Disney APS, Mathew TH, Amiss N. Risk factors associated with the development of squamous cell carcinomas in immunosuppressed renal transplant recipients. Clin Transplant 1992; 6:202-16.
6. Dyall-Smith D, Ross JB. Cutaneous malignancies in renal transplant recipients from Nova Scotia, Canada. Australas J Dermatol 1995; 36:79-82.
7. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40:177-86.
8. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Fauchald P. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transplant Proc 1999; 31:1120.
9. Clancy CJ, Nguyen MH. Long term voriconazole and skin cancer: is there cause for concern? Curr Infect Dis Rep 2011; 13:536-43.
10. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc 1997; 29:828-30.
11. Sole A. Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B. Int J Antimicrob Agents 2008; 32:161-5.
12. Voriconazole [package insert]. New York: Pfizer, 2009.
13. Racette AJ, Roenigk HH Jr, Hansen R, Mendelson D, Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol 2005; 52 (5 suppl. 1):S81-5.
14. Denning D, Griffiths C. Mucocutaneous retinoid effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001; 26:648-53.
15. Cowen EC, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermato 2010; 62:31-7.
16. McCarthy K, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44:55-6.
17. Rondeau S, Couderc L, Dominique S, et al. High frequency of voriconazole-related phototoxicity in cystic fibrosis patients. Eur Respir J 2012; 39:782-4.
18. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:649-63.
19. Swanson HI. Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective. Chem Biol Interact 2004; 149:69-79.
20. Angeles JCB, Cleaver J, Feeney L, Oh D, Arron S. Voriconazole does not potentiate photo damage from UVB exposure. J Clin Exp Dermatol Res 2013; 4:173.
21. Epaulard O, Leccia MT, Blanche S, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect 2011; 41:639-45.
22. Vanacker A, Fabre G, Van Dorpe J, Peetermans WE, Maes B. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant 2008; 8:877-80.
23. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62:31-7.
24. Feist A, Lee R, Osborne S, Lane J, Yung G. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant 2012; 31:1177-81.
25. Vadnerkar A, Nguyen H, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29:1240-4.
26. Singer J, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31:694-9.
27. Epaulard O, Saint-Raymond C, Villier C, et al. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbial Infect 2010; 16:1362-4.
28. Zwald FO, Spratt M, Lemos B, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38:1369-74.
29. McLaughlin JM, Equils O, Somerville KT, et al. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. Transpl Infect Dis 2013; 15:329-43.
30. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681-91.
31. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61:274-8.
32. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355:51-65.
33. Markovic SN, Erikson LA, Rao RD, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention and diagnosis. Mayo Clin Proc 2007; 82:364-80.
34. Mikus G, Scholz I, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011; 12:861-72.
35. Scholz I, Oberwittler H, Riedel K, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharm 2009; 68:906-15.
36. Markantonis SL, Katelari A, Pappa E, Doudounakis S. Voriconazole pharmacokinetics and photosensitivity in children with cystic fibrosis. J Cys Fibros 2012; 11:246-52.
37. Berge M, Guillemain R, Tregouet DA, et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 2011; 67:253-60.